For instance, the PACIFIC trial demonstrated that durvalumab, an anti-PD-L1 antibody, significantly prolonged progression-free survival when administered shortly after chemoradiotherapy in patients with stage III non-small-cell lung cancer (NSCLC) [23]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.